What is 4D Molecular Therapeutics's revenue?

4D Molecular Therapeutics (FDMT) generated $88.2M in revenue over the trailing twelve months, up 383560.9% year over year.

Is 4D Molecular Therapeutics profitable?

4D Molecular Therapeutics is not currently profitable: it reported a net loss of $228.3M over the trailing twelve months, a -174314.2% net margin.

What is 4D Molecular Therapeutics's earnings per share?

4D Molecular Therapeutics's diluted EPS over the trailing twelve months is $-3.86.

Where does 4D Molecular Therapeutics's income statement data come from?

Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

4D Molecular Therapeutics FDMT Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Total revenue	$3.05M-96.4%	$85.09M+94,444%	$90K+500%	$15K+7.1%	$14K+1,300%
Research and development	$64.98M+12.8%	$57.61M+16.5%	$49.44M+3.1%	$47.95M+17.8%	$40.7M-5.5%
General and administrative	$11.69M-8.5%	$12.77M+7.9%	$11.84M+2.8%	$11.52M-10.9%	$12.94M-0.7%
Other operating expenses	$76.67M+8.9%	$70.38M+14.9%	$61.28M+3.0%	$59.47M+10.9%	$53.64M-4.4%
Total operating expenses	$76.67M+8.9%	$70.38M+14.9%	$61.28M+3.0%	$59.47M+10.9%	$53.64M-4.4%
Operating income	-$73.62M—	$0+100%	-$61.19M-2.9%	-$59.46M-10.9%	-$53.62M+4.4%
Operating margin	-2,416.1%-2,416pp	0%+67,983pp	-67,983.3%+328,390pp	-396,373.3%-13,366pp	-383,007.1%+5,228,693pp
Interest income	$4.86M+3.4%	$4.7M+8.6%	$4.33M-10.9%	$4.86M-13.0%	$5.58M-13.7%
Other income (expense), net	$4.86M+3.8%	$4.68M+8.7%	$4.31M-10.2%	$4.8M-15.1%	$5.65M-12.4%
Net income	-$68.76M—	——	-$56.88M-4.1%	-$54.66M-13.9%	-$47.97M+3.4%
Net margin	-2,256.6%—	——	-63,195.6%+301,191pp	-364,386.7%-21,730pp	-342,657.1%+4,624,443pp
Diluted earnings per share	-$1.01—	——	-$1.01-3.1%	-$0.98-14.0%	-$0.86+4.4%
Basic earnings per share	-$1.01—	——	-$1.01-3.1%	-$0.98-14.0%	-$0.86+4.4%
Weighted-average shares, diluted	68.1M+17.5%	57.9M+3.2%	56.1M+0.4%	55.9M+0.3%	55.7M+3.3%
Weighted-average shares, basic	68.1M+17.5%	57.9M+3.2%	56.1M+0.4%	55.9M+0.3%	55.7M+3.3%
Other income, net (Note 6)	-$4K+81.8%	-$22K-4.8%	-$21K+65.6%	-$61K-191%	$67K+419%
Research and development expense	$64.98M+12.8%	$57.61M+16.5%	$49.44M+3.1%	$47.95M+17.8%	$40.7M-5.5%
Revenue From Contract With Customer Excluding Assessed Tax	$3.05M-96.4%	$85.09M+94,444%	$90K+500%	$15K+7.1%	$14K+1,300%
EBIT	-$73.62M—	$0+100%	-$61.19M-2.9%	-$59.46M-10.9%	-$53.62M+4.4%
EBITDA	-$72.35M-6,050%	$1.22M+102%	-$59.92M-2.8%	-$58.29M-10.9%	-$52.57M+4.5%
EBITDA	-$72.35M-6,050%	$1.22M+102%	-$59.92M-2.8%	-$58.29M-10.9%	-$52.57M+4.5%
EBITDA margin	-2,374.5%-2,376pp	1.4%+66,584pp	-66,582.2%+322,018pp	-388,600%-13,100pp	-375,500%+5,126,600pp
EBIT	-$73.62M—	$0+100%	-$61.19M-2.9%	-$59.46M-10.9%	-$53.62M+4.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about 4D Molecular Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is 4D Molecular Therapeutics's revenue?: 4D Molecular Therapeutics (FDMT) generated $88.2M in revenue over the trailing twelve months, up 383560.9% year over year.
Is 4D Molecular Therapeutics profitable?: 4D Molecular Therapeutics is not currently profitable: it reported a net loss of $228.3M over the trailing twelve months, a -174314.2% net margin.
What is 4D Molecular Therapeutics's earnings per share?: 4D Molecular Therapeutics's diluted EPS over the trailing twelve months is $-3.86.
Where does 4D Molecular Therapeutics's income statement data come from?: Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.